INT96145

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2001
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 7
Disease Relevance 5.61
Pain Relevance 1.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
saliva 3
brain 1
HLA-S (Homo sapiens)
Pain Link Frequency Relevance Heat
Multiple sclerosis 168 100.00 Very High Very High Very High
Inflammation 6 98.96 Very High Very High Very High
corticosteroid 6 97.76 Very High Very High Very High
Neuritis 6 97.16 Very High Very High Very High
Chronic pancreatitis 1 83.20 Quite High
rheumatoid arthritis 6 48.72 Quite Low
imagery 12 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Demyelinating Disease 174 100.00 Very High Very High Very High
Pancreatic Cancer 8 100.00 Very High Very High Very High
Chronic Hepatitis 1 99.22 Very High Very High Very High
Disease 82 99.20 Very High Very High Very High
INFLAMMATION 6 98.96 Very High Very High Very High
Systemic Lupus Erythematosus 12 97.76 Very High Very High Very High
Optic Neuritis 6 97.16 Very High Very High Very High
Hepatocellular Cancer 2 96.56 Very High Very High Very High
Recurrence 18 96.36 Very High Very High Very High
Gallbladder Neoplasms 2 95.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
When patients with acute or chronic hepatitis were excluded from analysis, the mean sHLA-I level in patients with pancreatic cancer was significantly higher than that of normal controls (p < 0.01) and patients with benign disease (p < 0.01), hepatocellular carcinoma (p < 0.01), gallbladder cancer (p < 0.05), and cholangiocarcinoma (p < 0.05).
Positive_regulation (higher) of sHLA-I associated with gallbladder neoplasms, chronic hepatitis, cholangiocarcinoma, hepatocellular cancer, pancreatic cancer and disease
1) Confidence 0.46 Published 2001 Journal Hum. Immunol. Section Abstract Doc Link 11390036 Disease Relevance 1.79 Pain Relevance 0.08
Of particular interest, the increase in sHLA-II values was associated with a decline on brain MRI activity as demonstrated by post-contrast T1-weighted axial brain images.
Positive_regulation (increase) of sHLA-II in brain
2) Confidence 0.31 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.24 Pain Relevance 0.12
Preliminary evidence suggests that patients with systemic lupus erythematosus (SLE) are at increased risk of developing active disease in the presence of high sHLA-I levels in the saliva, while sHLA-II level has not been observed to be elevated in rheumatological diseases [11].
Positive_regulation (elevated) of sHLA-II in saliva associated with disease and systemic lupus erythematosus
3) Confidence 0.31 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.90 Pain Relevance 0.21
However, the serum level of sHLA-I is significantly elevated in patients with various inflammatory diseases [5-8] although this is not necessarily the case for serum sHLA-II levels [9,10].
Positive_regulation (elevated) of sHLA-I associated with inflammation and disease
4) Confidence 0.31 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.51 Pain Relevance 0.05
On the other hand, sHLA-II in the serum of untreated MS patients was found to be significantly elevated compared to values obtained from MS patients receiving corticosteroid treatment. [12] Hypothetically, one would expect the measurement of sHLA in CSF would be most likely to reflect CNS disease activity.
Positive_regulation (elevated) of sHLA-II associated with corticosteroid, multiple sclerosis and disease
5) Confidence 0.21 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 1.30 Pain Relevance 0.40
In the present study, longitudinal measurement of saliva sHLA-II levels over a six month period demonstrated elevation of saliva sHLA-II levels in association with IFN ?
Positive_regulation (elevation) of sHLA-II in saliva
6) Confidence 0.18 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.57 Pain Relevance 0.22
At six months, all subjects exhibited a one-grade or greater decrease in their EDSS scores (p < 0.001) which occurred in association with elevated levels of saliva sHLA-II levels at month 6.


Positive_regulation (elevated) of sHLA-II in saliva
7) Confidence 0.18 Published 2007 Journal J Neuroinflammation Section Body Doc Link PMC1939839 Disease Relevance 0.29 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox